arrow
S

Susanna Akiki

Hamad Medical Corporation
H指数:17
被引数:1,963

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Post-cytotoxic myeloid neoplasms: a comprehensive analysis of clinicopathologic, genetic profile, latency determinants, and potential prognostic predictors- a single centre study

细胞毒治疗后髓系肿瘤:临床病理、基因谱、潜伏期决定因素及潜在预后预测因子的综合分析——一项单中心研究

2025-10-230
OA
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
2020-02-2584
OAAI
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (vol 32, pg 345, 2019)
LEUKEMIA
IF13.4
2020-01-142
OAAI
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
LEUKEMIA
IF13.4
2019-03-1162
OAAI
International external quality assurance of JAK2 V617F quantification
2018-12-087
OAAI
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
LEUKEMIA
IF13.4
2016-04-2546
OAAI
Assessment of Minimal Residual Disease in Standard-Risk AML

标准风险AML患者微小残留病的评估

2016-02-04667
OA
Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature
2015-08-0158
OAAI
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
LEUKEMIA
IF13.4
2014-07-1865
OAAI
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
LEUKEMIA
IF13.4
2013-07-17101
OAAI